Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
The company’s stock traded at approximately $64.32 per share 10 years ago. If you had invested $10,000, you could have bought roughly 155 shares. Currently, shares trade at $193.34, meaning your investment’s value could have grown to $30,059 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years.
Don’t Miss:
AbbVie’s dividend yield is currently 3.39%. Over the last 10 years, it has paid about $45.67 in dividends per share, which means you could have made $7,100 from dividends alone.
Summing up $30,059 and $7,100, we end up with the final value of your investment, which is $37,159. This is how much you could have made if you had invested $10,000 in AbbVie stock 10 years ago. This means a total return of 271.59%. In comparison, S&P 500 total return for the same period is 221.50%.
AbbVie has a consensus rating of “Buy” and a price target of $200.03 based on the ratings of 34 analysts. The price target implies more than a 3% potential upside from the current stock price.
Trending: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation.
On April 25, the company announced its Q1 2025 earnings, posting adjusted EPS of $2.46, up 6.5% year-over-year, and beating the consensus of $2.38, as reported by Benzinga.
The pharmaceutical giant reported sales of $13.34 billion, coming in above the consensus of $12.92 billion.
“AbbVie’s first-quarter results were well ahead of our expectations and reflect an excellent start to the year,” said CEO Robert Michael. “The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term.”
The company raised its full-year 2025 adjusted EPS from the range of $11.99 to $12.19 to $12.09 to $12.29, compared to the consensus of $12.17.
